Free Trial
NASDAQ:LTRN

Lantern Pharma (LTRN) Stock Price, News & Analysis

Lantern Pharma logo
$2.95 +0.01 (+0.34%)
(As of 10:25 AM ET)

About Lantern Pharma Stock (NASDAQ:LTRN)

Key Stats

Today's Range
$2.90
$2.96
50-Day Range
$2.94
$4.07
52-Week Range
$2.90
$11.99
Volume
8,975 shs
Average Volume
130,984 shs
Market Capitalization
$31.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Lantern Pharma Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
22nd Percentile Overall Score

LTRN MarketRank™: 

Lantern Pharma scored higher than 22% of companies evaluated by MarketBeat, and ranked 859th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Lantern Pharma are expected to grow in the coming year, from ($1.90) to ($1.86) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lantern Pharma is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lantern Pharma is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lantern Pharma has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Lantern Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    2.06% of the float of Lantern Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Lantern Pharma has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lantern Pharma has recently decreased by 6.39%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Lantern Pharma does not currently pay a dividend.

  • Dividend Growth

    Lantern Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.06% of the float of Lantern Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Lantern Pharma has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lantern Pharma has recently decreased by 6.39%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Lantern Pharma has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Lantern Pharma this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Lantern Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.31% of the stock of Lantern Pharma is held by insiders.

  • Percentage Held by Institutions

    Only 28.62% of the stock of Lantern Pharma is held by institutions.

  • Read more about Lantern Pharma's insider trading history.
Receive LTRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantern Pharma and its competitors with MarketBeat's FREE daily newsletter.

LTRN Stock News Headlines

Lantern Pharma doses first patient in LP-300 trial expansion cohort
LTRN: Pediatric Rare Cancer in Focus
My #1 Pre IPO Trade for 2025 – NAME and TICKER
One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...
Lantern Pharma Advances AI-Driven Cancer Therapies
See More Headlines

LTRN Stock Analysis - Frequently Asked Questions

Lantern Pharma's stock was trading at $4.28 at the start of the year. Since then, LTRN shares have decreased by 31.3% and is now trading at $2.94.
View the best growth stocks for 2024 here
.

Lantern Pharma Inc. (NASDAQ:LTRN) issued its earnings results on Thursday, August, 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.55) by $0.09.

Lantern Pharma (LTRN) raised $26 million in an initial public offering on Thursday, June 11th 2020. The company issued 1,600,000 shares at a price of $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers.

Lantern Pharma's top institutional investors include Westside Investment Management Inc. (0.28%). Insiders that own company stock include Leslie W Kreis and Aaron GL Fletcher.
View institutional ownership trends
.

Shares of LTRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lantern Pharma investors own include NVIDIA (NVDA), Tesla (TSLA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Intel (INTC), Meta Platforms (META) and NIO (NIO).

Company Calendar

Last Earnings
8/08/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/17/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LTRN
Fax
N/A
Employees
20
Year Founded
2013

Profitability

Net Income
$-15,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.76 per share

Miscellaneous

Free Float
9,997,000
Market Cap
$31.71 million
Optionable
Optionable
Beta
1.58

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (NASDAQ:LTRN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners